Stock Events

Stock Events

Invion Limited 

$0.036900
5
+$0.00+0% Tuesday 20:00

Statistics

Day High
0.0018
Day Low
0.0018
52W High
0.0369
52W Low
0.0018
Volume
2
Avg. Volume
0
Mkt Cap
4.03M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30AugExpected
Q2 2021
Q4 2021
Q2 2022
Q3 2022
Q2 2023
Q4 2023
Q2 2024
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-1,430.31%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
266,242.9Revenue
-3.81MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. is a global healthcare company that develops medications and vaccines, including treatments in the oncology sector, directly competing with Invion's focus on cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol-Myers Squibb is involved in biopharmaceuticals, particularly in cancer and immune system related therapies, overlapping with Invion's research and development in photodynamic therapies for cancer.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. is a large pharmaceutical company with a broad product line that includes oncology drugs, competing in the same market as Invion's cancer treatment technologies.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly and Company focuses on pharmaceuticals including cancer treatments, which competes with Invion's therapeutic approaches in oncology.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a strong presence in the development of cancer treatments, particularly in areas that might overlap with Invion's therapeutic technologies.
Novartis
NVS
Mkt Cap304.1B
Novartis AG is known for its extensive research and development in healthcare, including new cancer therapies that could compete with Invion's products.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, Inc. specializes in drugs for serious diseases including cancer, directly competing with Invion's focus areas.
AMGEN
AMGN
Mkt Cap236.38B
Amgen Inc. is a biotech firm focusing on human therapeutics, including cancer treatments that could rival Invion's product offerings.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a major player in diagnostics and pharmaceuticals, including cancer drugs, competing in the same space as Invion.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson engages in the development of pharmaceuticals, including oncology, which competes with Invion's cancer therapies.

About

Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as those found in the lung, prostate, ovaries, and in cases of mesothelioma. The company engages in strategic collaborations to further its research and development efforts. It holds an R&D agreement with the Hudson Institute of Medical Research, partnering on several projects related to the Photosoft technology for cancer treatment. Additionally, Invion has established a research pact with the Peter MacCallum Cancer Centre to carry out pre-clinical and in-vitro studies focusing on its IVX-PDT photodynamic therapy for ano-genital cancers, including penile and anal forms. Established in 2000, Invion Limited is based in Melbourne, Australia.
Show more...
CEO
Thian Chew
Employees
4
Country
Australia
ISIN
AU000000IVX4
WKN
000A1J3RR

Listings

AU
AU
IVX.AU
F
DE
7C8.F
OTC Link
US
IVIXF

0 Comments

Share your thoughts

FAQ

What is Invion Limited stock price today?▼
The current price of IVIXF is $0.04 USD — it has increased by +0% in the past 24 hours. Watch Invion Limited stock price performance more closely on the chart.
What is Invion Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Invion Limited stocks are traded under the ticker IVIXF.
Is Invion Limited stock price growing?▼
IVIXF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Invion Limited has showed a +0% increase.
What is Invion Limited market cap?▼
Today Invion Limited has the market capitalization of 4.03M
What were Invion Limited earnings last quarter?▼
IVIXF earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Invion Limited revenue for the last year?▼
Invion Limited revenue for the last year amounts to 266,242.9 USD.
What is Invion Limited net income for the last year?▼
IVIXF net income for the last year is -3.81M USD.
How many employees does Invion Limited have?▼
As of September 11, 2026, the company has 4 employees.
In which sector is Invion Limited located?▼
Invion Limited operates in the Health & Wellness sector.
When did Invion Limited complete a stock split?▼
The last stock split for Invion Limited was on November 20, 2024 with a ratio of 1:100.
Where is Invion Limited headquartered?▼
Invion Limited is headquartered in Melbourne, Australia.